Merck & Co completed the acquisition of drug developer Immune Design for nearly $300m, to gain access to its immunotherapy programs. Merck paid $5.8 in cash for each share of Immune Design. “Merck has a rich history of discovery and innovation and a strong track record of developing meaningful therapeutics and vaccines. We believe this agreement creates shareholder value by positioning our technologies and capabilities for long-term success with a leading, research-driven biopharmaceutical company.” Carlos Paya, Immune Design president and chief executive officer.